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Background: In April 2003, Médecins Sans Frontières launched an HIV/AIDS programme to provide free HAART to
HIV-infected patients in Laos. Although HIV prevalence is estimated as low in this country, it has been increasing in
the last years. This work reports the first results of an observational cohort study and it aims to identify the principal
determinants of the CD4 cells evolution and to assess mortality among patients on HAART.
Methods: We performed a retrospective database analysis on patients initiated on HAART between 2003 and 2009
(CD4<200cells/μL or WHO stage 4). We excluded from the analysis patients who were less than 16 years old and
pregnant women. To explore the determinants of the CD4 reconstitution, a linear mixed model was adjusted. To
identify typical trajectories of the CD4 cells, a latent trajectory analysis was carried out. Finally, a Cox
proportional-hazards model was used to reveal predictors of mortality on HAART including appointment delay
greater than 1 day.
Results: A total of 1365 patients entered the programme and 913 (66.9%) received an HAART with a median CD4
of 49 cells/μL [IQR 15–148]. High baseline CD4 cell count and female gender were associated with a higher CD4
level over time. In addition, this gender difference increased over time. Two typical latent CD4 trajectories were
revealed showing that 31% of women against 22% of men followed a high CD4 trajectory. In the long-term,
women were more likely to attend appointments without delay. Mortality reached 6.2% (95% CI 4.8-8.0%) at 4
months and 9.1% (95% CI 7.3-11.3%) at 1 year. Female gender (HR=0.17, 95% CI 0.07-0.44) and high CD4 trajectory
(HR=0.19, 95% CI 0.08-0.47) were independently associated with a lower death rate.
Conclusions: Patients who initiated HAART were severely immunocompromised yielding to a high early mortality.
In the long-term on HAART, women achieved a better CD4 cells reconstitution than men and were less likely to
die. This study highlights important differences between men and women regarding response to HAART and
medical care, and questions men’s compliance to treatment.Background
Highly active antiretroviral therapy (HAART) has clearly
reduced morbidity and mortality of HIV-infected patients
both in industrialized and developing countries [1-3].
The majority of HIV-infected people live in resource-
poor settings where programmes have been launched to
provide free HAART. The efficacy and the feasibility of
such programmes have been largely proved [4-6]. In* Correspondence: mathieu.bastard@geneva.msf.org
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reproduction in any medium, provided the or2009, antiretroviral therapy coverage was estimated at
37% in Sub-Saharan Africa and 31% in East, South and
Southeast Asia [7].
In Asia, the first case of AIDS was reported in 1984.
The actual HIV prevalence is low but several countries
show growing HIV epidemics [7,8]. In Lao People’s
Democratic Republic (Lao PDR), the first HIV infected
patient was detected in 1990 but the HIV epidemiology
is still not very well documented. The overall prevalence
seems to have increased over the past years and is esti-
mated at 0.2% [0.2; 0.4%] in 2009 but this figure could be
underestimated given the very few data available [7]. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and cross-border migration is recognized as a key factor of
the dynamic of the epidemic. Several studies and reports
show a higher prevalence among men who have sex with
men (5.6%), female migrants (0.8%) and service women
(0.4%) [9-12]. In order to prevent HIV infection, a 100%
Condom Use Programme and the HIV/AIDS/STIs Plan
for Lao PDR with twelve priority strategies have been
developed [13,14].
In July 2001, Médecins Sans Frontières (MSF) opened
a HIV/AIDS project in Savannakhet Provincial Hospital
in Lao PDR to provide prophylaxis and treatment for op-
portunistic infections for HIV-infected patients. In April
2003, MSF started a programme of free antiretroviral dis-
tribution in Savannakhet Hospital which became at that
time the only place in the country to provide HAART to
HIV/AIDS-infected patients.
Several studies on cohorts of HIV-infected patients re-
ceiving HAART in Thailand and Cambodia have been
published but to date, there is no equivalent publication on
the outcomes of patients on-HAART in Lao PDR [15-20].
To fill this gap, we conducted a retrospective analysis on a
database made available to us by the Ministry of health/
Center for HIV and STI and MSF in order to report the
first results on patients receiving HAART at Savannakhet
Provincial Hospital, located on the Thai-Lao border, be-
tween April 2003 and June 2009. This work aims at asses-
sing immune recovery and survival of patients on HAART.
Methods
Patients
Patients included in this retrospective analysis entered the
MoH-MSF programme of free HAART distribution be-
tween April 2003 and June 2009. We excluded from ana-
lysis patients who were less than 16 years old and pregnant
women. Patients started on HAART if they met one of the
following criteria: (1) CD4 cell count < 200 cells/μL irre-
spective of WHO clinical stage; (2) WHO clinical stage 4
irrespective of CD4 cell count. Date of HAART initiation
for eligible patients ranged between September 2003 and
June 2009.
Main initial regimens were triple-drug combinations
made of two nucleoside reverse transcriptase inhibitor +
one non-nucleoside reverse transcriptase inhibitor.
HIV testing, HAART, treatment of opportunistic infec-
tions (including tuberculosis), laboratory monitoring and
transportations of patients were free of charge for eli-
gible patients.
Follow-up of the patients
After a first visit at HAART initiation, patients were
followed-up at week 2 and 4, and then, once a month at
Savannakhet Provincial Hospital. After 6 months on
HAART and if there were no complaints from the patients,the follow-up took place every 3 months. The CD4 cell
count was monitored every 6 months, but no measure-
ment of viral load was available. A paper-based system was
used by the medical team to allow the clinical follow-up of
the patients. Some key data on patients and follow-up were
collected to produce activity reports using FUCHIA 1.6.1
software (Epicentre, Paris).
In October 2006, MSF opened a second treatment
centre in capital Vientiane allowing the transfer of pre-
HAART and on-HAART patients who originally lived in
or around Vientiane. No information on patients trans-
ferred to Vientiane could be retrieved so they were cen-
sored at date of transfer. We considered a patient as lost
to follow-up if their last visit preceded the closure date
of the database by 6 months and if he was not dead and
had not been transferred to Vientiane.
Data analysis
We performed a retrospective analysis on anonymized
data, captured with Fuchia, made available to us by
MoH-MSF. An internal unique key was generated by the
system to link the patients’ visits so that it was impos-
sible to identify a patient. The database was locked on
30th June 2009. The CD4 cell counts not available at
HAART initiation (D0) were retrieved from 15 days be-
fore to 15 days after D0, and in a median time of 34 days
before D0 for those with still missing CD4 cell count.
Baseline characteristics of men and women were com-
pared using Fisher’s exact test for categorical variables
and Wilcoxon test for continuous variables.
We estimated the median progression of CD4 cells on
HAART. We fitted a random-intercept linear mixed model
for repeated measures using all available CD4 measure-
ments at each time point to explore the effect of several
characteristics of patients at HAART initiation: age, gender,
Body mass index (BMI), WHO clinical stage, CD4 cell
count and haemoglobin level. We also fitted a latent trajec-
tory model, both for men and women, with a latent vari-
able characterizing different patterns of CD4 cells over
time [21]. This method aims at identifying typical latent
trajectories of CD4 cells based on individual CD4 cells
measures over time, as well as the prevalence of each latent
trajectory. To model these trajectories, a polynomial func-
tion of time on HAART was considered. Then, we esti-
mated, for each patient, a membership probability to each
trajectory, and we assigned a unique trajectory to a patient
by taking the maximum membership probability. Each pa-
tient has their own immune recovery over time, so it is im-
portant to underline that one typical trajectory does not
describe entirely a given patient’s CD4 evolution. This kind
of analysis may be affected by the number of CD4 mea-
surements over time per patient. To validate this approach,
we have analyzed the membership probabilities according
to the number of CD4 measurements for each patient.
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ments, defined as attending the visit the exact scheduled
day (or before), over time on HAART using mixed-effect
logistic regression.
The participation time on HAART was calculated as the
time between D0 and the date of last visit, the date of
transfer or the date of death. We described the mortality
on HAART using Kaplan-Meier curves and log-rank tests.
A Cox proportional-hazards model was adjusted to explore
the link between typical latent CD4 trajectories and mor-
tality, thus baseline CD4 count was not included because
its effect was captured by the latent trajectories. Other pos-
sible risk factors at HAART initiation such as age, gender,
Body mass index (BMI), WHO clinical stage and haemo-
globin level were considered in the analysis. Punctuality of
scheduled appointments was also investigated. Propor-
tional hazards (PH) assumption was checked by testing the
Schoenfeld residuals. Because gender appeared to violate
the PH assumption, time was split at 9 months and the ef-
fect of gender was thus estimated independently before
and after 9 months on HAART.
Statistical analyses were performed with Stata 10.1
(Stata Corporation, College Station, Texas, USA) soft-
ware using the generalized linear latent and mixed
model (GLLAMM) framework [22].
Ethical clearance
This research followed the principles of the Helsinki
Declaration, 2004 amendment and analysis plan wasTable 1 Patients’ characteristics at HAART initiation, Savanna
Characteristic a Men (N=507)
Age (years)
Median [IQR] 33 [29 – 38]
WHO clinical stage
Stage 4 316 (62.3%)
Stage 3 143 (28.2%)
Stage 2 35 (6.9%)
Stage 1 13 (2.6%)
CD4 cell count (cells/μL) b
Median [IQR] 41 [12 – 130]
< 50 236 (55.3%)
50-199 144 (33.7%)
≥ 200 47 (11.0%)
Body mass index (kg/m2) c
Median [IQR] 18.7 [17.1 – 20.7]
Haemoglobin level (g/dL) d
Median [IQR] 11.6 [9.9 – 13.2]
a 1 missing value on gender.
b 138 missing values: 80 for men, 58 for women.
c 9 missing values: 7 for men, 2 for women.
d 383 missing values: 211 for men, 172 for women.approved by the Ministry of Health – Centre for HIV,
AIDS and STIs (MoH/CHAS) of Lao PDR which
granted access to the anonymized data. This retrospect-
ive data analysis was performed on routinely collected
data which were fully anonymized and involved no risk
for participants. Verbal informed consent was obtained
from patients during the first visit, and therefore, their
first inclusion into the database.
Results
A total of 1365 patients were registered in the database.
Among them, 3 were excluded because there were no data
recorded for them and 134 were excluded because they
were less than 16 years old. Before receiving HAART, 127
patients died, 30 were transferred to Vientiane and 71
were lost to follow-up. Among the 1000 patients alive
and followed, 913 (91.3%) were started on HAART and
included in the analyses where as 87 were not initiated
on ART because they were not eligible at the closing
date of the database.
Patients’ characteristics at HAART initiation are pre-
sented in Table 1. Median age was 32 years [interquartile
range (IQR) 28–38] and 507 patients (55.6%) were men.
Majority of patients were at an advanced stage of HIV
disease: 261 (28.6%) with WHO stage 3 and 531 (58.2%)
with WHO stage 4. The median baseline CD4 cell count
was 49 cells/μL [IQR 15–148] (n=775). Women had a
significant higher CD4 cell count than men (median 65
vs. 41 cells/μL, P=0.002). The median BMI (18.5 kg/m2khet, Lao PDR, 2003–2009
Women (N=405) P Overall (N=913)
32 [27 – 37] 0.003 32 [28 – 38]
215 (53.1%) < 0.001 531 (58.2%)
117 (28.9%) 261 (28.6%)
44 (10.9%) 79 (8.6%)
29 (7.1%) 42 (4.6%)
65 [20 – 166] 0.002 49 [15 – 148]
155 (44.7%) 391 (50.5%)
133 (38.3%) 278 (35.9%)
59 (17.0%) 106 (13.6%)
18.2 [16.4 – 20.5] 0.07 18.5 [16.8 – 20.6]
11.3 [9.6 – 12.7] 0.07 11.4 [9.7 – 13.1]
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(11.4 g/dL [IQR 9.7-13.1], n=530) did not strongly differ by
gender (P = 0.07). The two main initial regimens were:
stavudine/lamivudine/neviparine (TriomuneW) (65.1%) and
stavudine/lamivudine/efavirenz (33.1%).
During HAART, the median CD4 cell gain increased
strongly in the first year and attained +156 cells/μL [IQR
104–231] at 12 months (n=335). Then, it increased
slowly from +191 cells/μL [IQR 121–269] at 18 months
(n=336) to +294 cells/μL [IQR 162.5-405] at 42 months
(n=152) before stabilizing.
The results of the random-intercept linear mixed
model are reported in Table 2. Patients with a higher
baseline CD4 cell count achieved a higher long-term
CD4 reconstitution, indeed patients with CD4 cell
count between 50 and 199 cells/μL (respectively
more than 200 cells/μL) had on average +82 cells/μL
(respectively +194 cells/μL) more than patients with
less than 50 cells/μL at initiation after 2.5 years on
HAART. However, the CD4 cells increased faster for
patients with a lower baseline CD4 cell count (sig-
nificant interaction between baseline CD4 cell count
and time). Indeed, patients who had a baseline CD4
cell count < 50 cells/μL gained, on average per year,
about +12 cells/μL and +20 cells/μL more than
patients who had a baseline CD4 cell count between
50 and 199 cells/μL and patients who had more than
200 cells/μL, respectively. In addition, after adjusting for
baseline CD4 count, women had on average +38 cells/μLTable 2 Predictors of CD4 reconstitution identified by the
random-intercept linear mixed model (N=774),
Savannakhet, Lao PDR, 2003–2009
Predictors Coefficient 95% CI
Time since HAART initiation (year) a
Linear trend 25.15 (18.36; 31.93)*
Quadratic trend −15.36 (−18.01; −12.71)*
Cubic trend 6.48 (5.04; 7.92)*
Gender b
Intercept 38.54 (23.70; 53.38)*
Slope deviation 14.82 (9.52; 20.12)*
CD4 at HAART initiation c
Intercept
50–199 cells/μL 82.35 (66.74; 97.95)*
≥ 200 cells/μL 194.42 (169.29; 219.55)*
Slope deviation
50–199 cells/μL −11.64 (−17.12; −6.15)*
≥ 200 cells/μL −20.10 (−29.45; −10.74)*
* P < 0.001.
a Time was centered at 2.5 years on HAART.
b Reference group: men.
c Reference group: CD4 at HAART initiation < 50 cells/μL.more than men after 2.5 years on HAART. Furthermore,
the significant effect of the interaction term between
gender and time indicated that women gained on aver-
age about +15 cells/μL per year more than men. Finally,
variance of the random-intercept represented about 35%
of the total variance (p<0.001), showing an important
heterogeneity between patients.
The latent trajectory analysis reveals both for men
and women two typical latent trajectories of CD4 cells
over time (Figure 1). The first latent trajectory repre-
sented 78% of men and 69% of women, with a low
CD4 trajectory, achieving about 300 cells/μL after 60
months. The second latent trajectory represented 22%
of men and 31% of women who experienced a high
CD4 trajectory, reaching about 500 and 600 cells/μL
after 60 months for men and women, respectively. The
average membership probability was about 0.8 for
patients with a low number of CD4 measurements,
and tended to 1 for patients with higher number of
CD4 measurements.
Analysis of appointments revealed that 85.6% of visits
took place without delay and that the median delay was
2 days [IQR 1–7]. A significant interaction between gen-
der and time (in years) indicated a better punctuality of
appointments for women compared to men in the long-
term on HAART (Odds Ratio of interaction between
gender and time: 1.09; 95% CI 1.01-1.19).
The median participation time was 21.7 months [IQR
8.1-42.5] and the average interval between two visits was
1 month and 11 days. On HAART, 40 patients were lost
to follow-up (4.4%), 98 were transferred to Vientiane
(10.7%) and 107 died (11.7%). Cumulative probability of0
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Figure 1 Latent CD4 trajectories for men and women on
HAART, Savannakhet, Lao PDR, 2003–2009.
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1.16-3.19%) at 12 months and 5.33% (95% CI 3.72-7.63%)
at 30 months. Kaplan-Meier estimates of mortality
attained 6.2% (95% CI 4.8-8.0%), 7.7% (95% CI 6.1-9.7%)
and 9.1% (95% CI 7.3-11.3%) at 4, 9 and 12 months, re-
spectively. Mortality differed by the following factors:
CD4 cell count (Figure 2a, log-rank test: P=0.007) and
BMI (Figure 2b, log-rank test: P<0.001) at baseline, and
by the typical latent CD4 trajectories (Figure 2c, log-
rank test: P<0.001), showing a higher mortality amongAt risk:
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Figure 2 Kaplan-Meier estimates of mortality on HAART, Savannakhe
initiation (a); BMI at HAART initiation (b); the latent CD4 trajectories (c); andpatients with a low CD4 trajectory. In addition, mor-
tality seems higher for men after 9 months on HAART
(Figure 2d), but due to the violation of the PH assumption,
the log-rank test was not valid and we can not conclude of
a significant difference. Following our analysis plan, base-
line CD4 cell count was not included in the multivariate
Cox model, which showed that a high CD4 trajectory
over time (Hazard Ratio 0.19, 95% CI 0.08-0.47), female
gender after 9 months on HAART (HR 0.17, 95% CI
0.07-0.44) and a baseline BMI ≥ 18 kg/m2 (HR 0.39,At risk:
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t, Lao PDR, 2003–2009. Estimates stratified by: CD4 at HAART
gender (d).
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lower death rate (Table 3). However, gender before 9
months on HAART and attendance to clinical appoint-
ments were not associated with mortality.
Discussion
Throughout this retrospective study, a better long-term
immunologic reconstitution for women after HAART
initiation was pointed out. Two typical latent trajectories
of the CD4 cells for men and women were identified,
showing that about 31% of women had a high CD4 tra-
jectory against about 22% of men. In addition, a better
survival was independently associated to female gender
after 9 months and to patients with a high CD4 trajec-
tory on HAART.
Programme evaluation
A recent bulletin of the World Health Organization
(WHO) states that, on average, 21% of the patients are
lost to follow-up in the first 6 months after HAART initi-
ation in resource-limited settings [23]. In Sub-Saharan
Africa, a systematic review of HAART programmes
shows that around 40% of patients were lost to follow-up
after 2 years on HAART [24]. In addition, a recent meta-
analysis of the mortality of patients LTFU in resource-
limited settings reveals that 20 to 60% of the patients
LTFU have died [25]. The present analysis indicates a
low lost to follow-up rate showing a good compliance to
the programme. Moreover, the high frequency of the vis-
its at the hospital (on average every 1 month and 11 days)
underlines the good monitoring of the cohort.Table 3 Adjusted mortality rate ratios (95% confidence
interval) from Cox proportional-hazards model (N=840),
Savannakhet, Lao PDR, 2003–2009
Predictors HR 95% CI P
Latent CD4 trajectories
Low CD4 trajectory 1
High CD4 trajectory 0.19 (0.08; 0.47) < 0.001
Gender before 9 months on HAART
Men 1
Women 1.19 (0.69; 2.05) 0.53
Gender after 9 months on HAART
Men 1
Women 0.17 (0.07; 0.44) < 0.001
BMI at HAART initiation
< 18 kg/m2 1
≥ 18 kg/m2 0.39 (0.25; 0.60) < 0.001
Schoenfeld residuals.
Global chi-squared test: p=0.53; detailed chi-squared test: latent CD4
trajectories: p=0.09; gender before 9 months on HAART: p=0.64; gender after 9
months on HAART: p=0.89; BMI at HAART initiation: p=0.67.Immune reconstitution
As it has been reported in other studies conducted
in Southeast Asia, patients who start HAART were
severely immunocompromised [15,16,18]. Without
viral load measurements, WHO recommends to use
CD4 reconstitution to assess the efficacy of treatment
[26]. In this study, the median CD4 cells gain
increases with time on HAART and this progression
is comparable to the one observed in other low-
income countries [15,18-20,27,28].
As in other studies, the baseline CD4 cell count is a
strong predictor of immune reconstitution, indicating
that patients with higher baseline CD4 cell count achieve
a better immune recovery [29,30]. In addition, our find-
ings show that, overall, the CD4 cells increase faster for
the most immunocompromised patients. This suggests
that, in the long-term, the most immunocompromised
patients, surviving the early phase on HAART, could re-
store their immunity as well as the other patients. Tak-
ing together, these results argue in favour of an earlier
access to HAART and of an improvement in diagnosis
and treatment of opportunistic infections during first
months on treatment.
Several studies on large cohorts and long follow-up
have failed to associate gender and immune reconsti-
tution [31,32]. This study shows that women achieve
a better immune recovery on HAART independently
of the baseline CD4 cell count. This could be
explained by better adherence for women, but we are
unable to check this hypothesis because of the lack
of adherence measurements. Although gender is gen-
erally not associated with adherence, comprehensive
studies in Burkina Faso have shown a better use of
health care facilities for women in the West of Africa
as well as a better communication with health care
workers on disease and treatment issues and argue in
favour of better adherence behaviour among women
[33-35]. Moreover, a higher long-term adherence to
HAART among women has recently been shown in
Senegal [36]. In this study, we have shown that
women attend more regularly follow-up visits over
time than men. This indicator, which could be used
as a proxy of adherence, argues in favour of a better
adherence for women. Another explanation could be
that men who are frequently migrant worker do not
adhere entirely to HAART because they could not
refill on time [10-12]. In addition, a recent study in
Thailand shows that women have more and earlier
access to antiretroviral treatments [37]. Other factors
like the stigma of HIV infection, family responsibil-
ities, work or homophobia could impact on treat-
ment access for men [38-40]. It has been shown that
HIV-negative women had higher CD4 cell count than
men in Africa [41]. However, it does not impact on
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for baseline CD4 cell count, a physiological differ-
ence in CD4 counts could explain a steeper slope for
women to return to their immunological equilibrium.
The latent trajectory analysis has identified two pat-
terns of the CD4 evolution both for men and women.
Overall, about a quarter of the patients followed a simi-
lar high CD4 trajectory, and about three quarters a lower
one. About a third of women achieved a high CD4 tra-
jectory whereas about a fifth of men achieved it. These
results are in line with the mixed model.
The prevalence of the two latent trajectories reflects
the distribution of baseline CD4 cell count. Indeed,
patients with a low CD4 cell count at HAART initiation
are more likely to follow a low CD4 trajectory. This
explains why the prevalence of the first latent trajectory
is high. Strength of this approach is that it describes the
typical evolution of the CD4 cells in that cohort and it
captures the effect of the low baseline CD4 count. The
high membership probability observed even for patients
with a low number of CD4 measurements allows us to
assign patients to a unique latent trajectory with confi-
dence. This is a new approach to explore different pat-
terns of the CD4 evolution and it could be generalized
to other longitudinal studies to reveal different patients’
behaviour over time.
Mortality
Half of the deaths occur in the first four months after
HAART initiation, showing a higher early mortality than
the one generally observed in low-income countries. A
recent scale-up of national antiretroviral therapy pro-
grammes in the Asia Pacific region shows that 50% of
mortality occurs in the first 6 months of therapy [42].
High early mortality has also been reported in sub-
Saharan Africa [43-46]. However, after 1 year on treat-
ment, mortality is about 9% which is similar to other
low-income countries [15,19,28,47,48]. A pooled analysis
from 18 developing countries has assessed the risk of
dying after 1 year at 5.8%, which is about twice as low as
in this cohort, as in other settings [49,50]. This early
mortality could be explained by the advanced stage of
infection and the low CD4 cell count of patients at en-
rollment, due to late presentation of patients [46]. As it
has already been reported, poor adherence could be
associated with increase in mortality [48,51,52].
Mortality differs by patients’ baseline characteristics
such as CD4 cell count and BMI. These relationships
have already been largely described both in low-income
and high-income countries [15,18,28,44,45,47,53-55].
As shown in an observational cohort in South Africa,
mortality is strongly associated with immune reconstitu-
tion during HAART [56]. Indeed, mortality differs by
the two latent CD4 trajectories with a fivefold risk ofdeath for the three quarters of patients following a low
CD4 trajectory. Introducing these trajectories as a cov-
ariate of the Cox model provide a new way to explore
the link between mortality and CD4 evolution on
HAART, as it captures simultaneously the baseline and
the reconstitution itself.
Our study also reveals a higher mortality among men.
This result is also reported in other studies [57-63]. Men
are more immunocompromised at HAART initiation
which suggests a late presentation, as reported in South
Africa [64]. Lower adherence and higher mobility among
men are also mentioned by programme managers in
Cambodia [58]. Here, the difference in mortality be-
tween men and women appears only after 9 months on
HAART. It is important to highlight that this effect is in-
dependent of the latent CD4 trajectories and BMI. This
result could point out sub-optimal care and treatment of
clinical events occurring among men after the first year
on treatment.
Limitations of the study
This study presents some limitations. First, we have no
information about outcomes of patients lost to follow-up
and transferred to Vientiane, which could bias the esti-
mated immune recovery and mortality in the cohort.
Adjusting mortality for loss to follow-up could correct
the estimates, but due to the low lost to follow-up rate in
this cohort, we did not use this method [65]. Then, be-
cause of technology availability and costs, viral load mea-
surements were not available at that time. In addition, no
data on adherence to antiretroviral was available.
Conclusions
This MSF programme where 913 patients initiated
HAART with a very severe immuno-suppression reveals
an important heterogeneity between patients and better
outcomes for women. Indeed, a quarter of the patients
present a high CD4 trajectory and women experience a
better immune recovery and lower mortality than men.
This study provides additional evidence for differences
between men and women, once on HAART and, in par-
ticular, a difficulty for men to maintain a long-term
compliance to treatment. Moreover, this study recom-
mends that clinicians and healthcare providers have to
pay special attention to men during treatment.
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